UniSA uses cookies to remember your preferences, analyse traffic, track usage patterns, and personalise content. In some instances, UniSA shares personal information collected by cookies with UniSA's third party service providers and Adelaide University (as UniSA's future successor). See our privacy notification for further details. To adjust your cookie settings, click 'More information'. By clicking 'Accept and continue', you consent to our use of cookies.
UniSA recommends the use of all cookies to provide you with the optimal experience while visiting our website. Choose below to accept the recommended settings or continue to adjust your individual preferences.
The medical radiations group is involved in the investigation and translation of various imaging modalities for the diagnosis of various cancers, and of novel radiation modalities to treat cancers. The group consists of research expertise across medical imaging, nuclear medicine and radiation therapy – all playing specific roles in diagnosis, staging, treatment and follow-up of cancers.
Radiation therapy is used in treatment of approximately 50% of cancer patients and contributes towards 40% of cancer cures. These days it is often used as part of multimodality treatment in combination with surgery, chemotherapy or even immunotherapy, therefore improving patient treatment outcomes even more.
The research of our group is multifaceted and includes:
Other research includes development of a proton beam line on a SAHMRI cyclotron for radiobiological experiments using proton beam; as the novel state-of-the-art radiation therapy beam modality currently being developed in Adelaide and in Australia.
In the area of nuclear medicine and theranostics, we are investigating the use of novel alpha emitting radionuclides to target cancer cells in a patient’s body; known as targeted alpha therapy.
Our group is renowned for world-class radio-biological modelling of radiation interactions with cells and cancers to predict biological outcomes post irradiation.
Other areas of research include development of new dosimetry and microdosimetry detectors to measure radiation dose at a cellular level. In collaboration with the Future Industries Institute, we’re also looking at the implementation and use of metallic nanoparticles (such as gold) as radio-sensitisers in radiation therapy for cancer, with the aim to maximise the damage to cancer cells while protecting healthy tissues.